# A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

> **NCT07128550** · PHASE3 · RECRUITING · sponsor: **Vir Biotechnology, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Viral Hepatitis

## Interventions

- **DRUG:** Tobevibart
- **DRUG:** Elebsiran
- **DRUG:** Bulevirtide

## Key facts

- **NCT ID:** NCT07128550
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2026-12
- **Final completion:** 2031-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07128550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07128550, "A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07128550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*